knowledge -WSS

knowledge

author：knowledge 2025-09-30 06:09:08 - browse：534

Illustration of a laptop on top of a TV with a hand sticking out, holding a newspaper. -- coverage from STAT — Adobe

WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription drug market.

Ads eviscerating and glorifying PBMs have been around for years. But they’ve intensified over the past three months as Congress scrutinizes PBMs’ role in shaping high drug prices. Over a half-dozen U.S. House and Senate Committees have started investigating PBMs, advancing bipartisan legislation to increase transparency in the industry; ban PBMs from charging more for a drug than what they pay (and pocketing the difference); and require them to pass all fees, rebates, and other payments they receive to insurers.

Lobbying groups have responded to this legislative push with dueling campaigns in the court of public opinion. On one side is the Pharmaceutical Care Management Association, the trade association representing PBMs, which argues that pharmaceutical companies are responsible for high drug prices. On the other side is the industry group PhRMA, which points the finger right back, saying that PBMs are really to blame. Both trade associations have launched ad campaigns worth millions of dollars, blanketing TV, radio, social media, print, and beyond.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

explore

knowledge

WSS

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Resistance to opioid

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Congress considering partial increase for doctor pay in Medicare

FDA approves first new drug developed for postpartum depression

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Wikipedia

knowledge

knowledge

23andMe had bad news about my health. I wish a person had delivered it

Report cites 'urgent' need to recruit more diverse clinical trial participants

What does generative AI mean for health care? We asked experts

Ebola vaccine can save some who are already sick, per new study

Medical leaders decry Supreme Court decision on affirmative action

Abbott's new heart device gets FDA advisory panel nod

Walensky prepares to leave CDC — and Congress — behind

Doctors on social media are being harassed and cyberbullied

After affirmative action ruling, medical educators look to 'holistic review'

Xenotransplantation trials will require adjusting expectations, experts say

Wikipedia

Mom launches Girl Scout troop for LGBTQ youth in Texas

Mom launches Girl Scout troop for LGBTQ youth in Texas

Juul documents reveal insider tactics on political lobbying

Bernie Sanders gets little from pharma CEOs on drug prices

Ebola vaccine can save some who are already sick, per new study

Novo: Oral version of Ozempic leads to 15% weight loss

explore

knowledge

focus

explore